摘要
目的:观察曲美他嗪与氯吡格雷联合治疗冠心病心绞痛对患者五聚素3(PTX-3)、内皮细胞特异性分子-1(ESM-1)、内皮素(ET)水平的影响。方法:选取2018年4月-2020年2月咸宁市第一人民医院收治的118例冠心病心绞痛患者为研究对象,采用随机数字表法分为对照组和观察组,每组59例。两组患者均给予补液、抗血小板、调脂、降压等常规治疗,对照组给予氯吡格雷治疗,观察组给予氯吡格雷联合曲美他嗪治疗。记录两组治疗前后PTX-3、ESM-1、ET、白细胞介素-18(IL-18)、核转录因子-κB(NF-κB)、超敏C反应蛋白(hs-CRP)、左室射血分数(LVEF),并评价两组疗效及安全性。结果:观察组和对照组的总有效率分别为93.22%(55/59)、79.66%(47/59),两组比较,差异有统计学意义(P<0.05)。治疗后,两组ESM-1、ET水平均较治疗前下降,观察组ESM-1、ET水平均低于对照组(P<0.05)。治疗后,两组IL-18、hs-CRP、NF-κB、PTX-3水平均较治疗前下降,观察组IL-18、hs-CRP、NF-κB、PTX-3水平均低于对照组(P<0.05)。治疗后,两组LVEF均较治疗前上升,观察组LVEF高于对照组(P<0.05)。观察组和对照组的不良反应发生率分别为5.08%、6.78%,两组比较,差异无统计学意义(P>0.05)。结论:曲美他嗪与氯吡格雷联合治疗冠心病心绞痛可调节相关因子的表达,改善心绞痛,疗效优于单用氯吡格雷。
Objective:To observe the effect of Trimetazidine combined with Clopidogrel on levels of pentraxin 3(PTX-3),endothelial cell speci molecule-1(ESM-1)and endothelin(ET)in patients with coronary heart disease and angina pectoris.Method:A total of 118 patients with coronary heart disease and angina pectoris who were admitted to Xianning First People's Hospital from April 2018 to February 2020 were selected as the research subjects.They were divided into the control group and the observation group according to the random number method,with 59 cases in each group.Patients in both groups were given routine treatments such as fluid replacement,antiplatelet,lipid regulation and antihypertensive.The control group was given Clopidogrel,and the observation group was given Clopidogrel combined with Trimetazidine.PTX-3,ESM-1,ET,interleukin-18(IL-18),nuclear factor-κB(NF-κB),hypersensitive C reactive protein(hs-CRP)and left ventricular ejection fraction(LVEF)were recorded in the two groups before and after treatment,and the efficacy and safety of the two groups were evaluated.Result:The total effective rates of the observation group and the control group respectively were 93.22%(55/59)and 79.66%(47/59),the difference was statistically significant between the two groups(P<0.05).After treatment,the levels of ESM-1 and ET in the two groups decreased compared to before treatment,and the levels of ESM-1 and ET in the observation group were lower than those in the control group(P<0.05).After treatment,the levels of IL-18,hs-CRP,NF-κB and PTX-3 in the two groups decreased compared to before treatment,and the levels of IL-18,hs-CRP,NF-κB and PTX-3 in the observation group were lower than those in the control group(P<0.05).After treatment,the LVEF of both groups increased compared to before treatment,and the LVEF of the observation group was higher than that of the control group(P<0.05).The incidence of adverse reactions in the observation group and the control group respectively was 5.08%and 6.78%,there was no statistical difference
作者
吴建辉
WU Jianhui(Xianning First People's Hospital,Hubei Province,Xianning 437000,China)
出处
《中国医学创新》
CAS
2023年第12期39-43,共5页
Medical Innovation of China
